SEC Form 8-K Summary
Registrant: MedTech Acquisition Corporation, not Trisalus Life Sciences, Inc., as identified in the request metadata. The report was filed in connection with an event occurring March 4, 2022, and was signed March 7, 2022.
Business Context and Reporting Period
This Form 8-K reports a change in the registrant’s board and committee composition. The filing does not provide operating results or a quarterly or annual reporting period.
Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other financial metrics.
Material Changes
- Ivan Delevic resigned effective March 4, 2022, from the Board of Directors and all other positions with the company.
- The filing states that the resignation was not due to any disagreement with the company.
- Thierry Thaure was appointed to the Board’s Audit Committee and was determined by the Board to be independent under applicable Nasdaq and SEC requirements.
- Following the appointment, the Audit Committee consisted of Thierry Thaure, Karim Karti, and Manuel Aguero, all identified as independent directors.
Guidance, Risks, and Unusual Items
No management guidance, outlook, contingencies, litigation, or unusual financial items are disclosed. The principal disclosed governance change is Mr. Delevic’s immediate resignation and Mr. Thaure’s Audit Committee appointment.
Key Facts to Verify
- Confirm that the filing relates to MedTech Acquisition Corporation, whose securities traded under MTAC, MTACU, and MTACW, rather than Trisalus Life Sciences, Inc.
- Verify the effective date and scope of Ivan Delevic’s resignation.
- Verify the independence status and current membership of the Audit Committee.
- Review subsequent filings for additional board, committee, or business-combination developments.